MRSANCT07748143
To Evaluate the Impact of MRSA Nasal Screen Implementation.
An observational study of MRSA, run by Methodist Health System at 1 site in United States.
Trial summary
To evaluate the impact of MRSA nasal screen implementation on duration of therapy and cost associated with vancomycin use. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- MRSA
- What is being tested?
- Duration of therapy, Direct Cost and Pharmacokinectic Monitoring
- How many people
- 21 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Oct 2019to 10 Jun 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The MRSA(Methicillin-resistant Staphylococcus aureus)nasal screen has been clearly established to have a strong negative predictive value in identifying patients not infected with MRSA(Methicillin-resistant Staphylococcus aureus).
Who may be able to join
- Age > 18 years
- Diagnosis of pneumonia
- Admission inpatient to Methodist Richardson Medical Center
- Treatment with vancomycin empirically
Who cannot join
- Age ≤ 18 years
- Patients with other confirmed gram positive infections
Trial locations and contacts
1 site in 1 country.
United States1 site
Methodist Dallas Medical Center- Clinical Research Institute
Dallas, Texas, 75203
About this study
Official title: The Effect of MRSA Nasal Screen Implementation on Duration of Therapy and Cost Associated With Vancomycin Use.
To evaluate the impact of MRSA nasal screen implementation on duration of therapy and cost associated with vancomycin use.
Read the detailed description
Routine blood and sputum cultures are often obtained inpatient for critically ill pneumonia patients. These tests, however, tend to have a high yield of false positives, leading to an increase in the use of broad spectrum antibiotics, specifically vancomycin. The Methicillin-resistant Staphylococcus aureus(MRSA) nasal screen is an antimicrobial stewardship tool that can be used to guide the treatment of community-acquired, hospital-acquired and ventilator-associated pneumonia. Due to its strong negative predictive value; a negative result can accurately indicate the absence of an MRSA infection in 96% of cases. Long-term treatment with vancomycin in patients with pneumonia is nephrotoxic and not always warranted. The implementation of an MRSA nasal screen in all patients with pneumonia treated with vancomycin has the potential to reduce vancomycin duration of therapy, decrease the risk of adverse effects and decrease the cost associated with vancomycin use.
- Conditions
- MRSA
- Being tested
- Duration of therapy, Direct Cost, Pharmacokinectic Monitoring, Hospital stay
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Duration of therapyOther
The final data will then be compared to determine if the duration of therapy and cost after implementation of the MRSA nasal screen if significantly different from before the implementation of the MRSA nasal screen.
Direct CostOther
Direct costs of vancomycin for each treatment arm (in US dollars).
Pharmacokinectic MonitoringOther
Number of vancomycin levels drawn for pharmacokinetic monitoring.
Hospital stayOther
Length of hospital stay in days
| Study group | Role | What they receive |
|---|---|---|
| The direct cost of vancomycin | The direct cost of vancomycin for each patient will then be calculated. An average duration of therapy and the average cost of therapy per patient will be calculated. Receives: Other: Duration of therapy; Other: Direct Cost; Other: Pharmacokinectic Monitoring; Other: Hospital stay |
What is being measured
The primary outcome is the main question the study is designed to answer.
Duration of therapy
To analyze duration of vancomycin in days.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted5 Aug 2026
- Study start1 Oct 2019
- Primary completion1 Jun 2026
- Study completion10 Jun 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MRSAStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 21 participants (actual)
Sponsor and investigators
- Lead sponsor
- Methodist Health System
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Daniel Betina, Principal investigator, Methodist Health System
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07748143
- Sponsor's protocol ID
- 042.PHA.2019.R
- Status last verified
- Jun 2026
- First submitted
- 8 Jun 2026
- Last updated
- 5 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of MRSA Nasal Screen Implementation on Duration of Therapy and Cost Associated With Vancomycin Use.
- ClinicalTrials.gov ID
- NCT07748143
- Acronym / sponsor ID
- 042.PHA.2019.R
- Conditions
- MRSA
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 21 participants (actual)
- Lead sponsor
- Methodist Health SystemUniversity, hospital or other
- Study start
- 1 Oct 2019 (actual)
- Primary completion
- 1 Jun 2026 (actual)
- Study completion
- 10 Jun 2026 (actual)
- First posted
- 5 Aug 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To evaluate the impact of MRSA nasal screen implementation on duration of therapy and cost associated with vancomycin use.
Detailed description
Routine blood and sputum cultures are often obtained inpatient for critically ill pneumonia patients. These tests, however, tend to have a high yield of false positives, leading to an increase in the use of broad spectrum antibiotics, specifically vancomycin. The Methicillin-resistant Staphylococcus aureus(MRSA) nasal screen is an antimicrobial stewardship tool that can be used to guide the treatment of community-acquired, hospital-acquired and ventilator-associated pneumonia. Due to its strong negative predictive value; a negative result can accurately indicate the absence of an MRSA infection in 96% of cases. Long-term treatment with vancomycin in patients with pneumonia is nephrotoxic and not always warranted. The implementation of an MRSA nasal screen in all patients with pneumonia treated with vancomycin has the potential to reduce vancomycin duration of therapy, decrease the risk of adverse effects and decrease the cost associated with vancomycin use.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| The direct cost of vancomycin | – | Other: Duration of therapy, Other: Direct Cost, Other: Pharmacokinectic Monitoring, Other: Hospital stayThe direct cost of vancomycin for each patient will then be calculated. An average duration of therapy and the average cost of therapy per patient will be calculated. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The MRSA(Methicillin-resistant Staphylococcus aureus)nasal screen has been clearly established to have a strong negative predictive value in identifying patients not infected with MRSA(Methicillin-resistant Staphylococcus aureus).
Key inclusion criteria (4 listed)
- Age > 18 years
- Diagnosis of pneumonia
- Admission inpatient to Methodist Richardson Medical Center
- Treatment with vancomycin empirically
Key exclusion criteria (2 listed)
- Age ≤ 18 years
- Patients with other confirmed gram positive infections
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Duration of therapyThe final data will then be compared to determine if the duration of therapy and cost after implementation of the MRSA nasal screen if significantly different from before the implementation of the MRSA nasal screen. | Other | The direct cost of vancomycin |
| Direct CostDirect costs of vancomycin for each treatment arm (in US dollars). | Other | The direct cost of vancomycin |
| Pharmacokinectic MonitoringNumber of vancomycin levels drawn for pharmacokinetic monitoring. | Other | The direct cost of vancomycin |
| Hospital stayLength of hospital stay in days | Other | The direct cost of vancomycin |
Primary outcome
Duration of therapy
Time frame: 1 year
To analyze duration of vancomycin in days.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Aug 2026.
Related trials for MRSA
Not yet recruiting
Farm-originated Antimicrobial Resistance Modeling: Exploring Humans-to-Animal Dissemination
Methicillin-Resistant Staphylococcus Aureus Colonization
Enrolling by invitationPhase 4
Does Staphylococcus Aureus Bacteremia Early Dual Therapy Improve Outcomes?
Staphylococcus Aureus Bacteremia
Not yet recruitingObservational study
Secondary Bacterial Infections and Nasal Colonization in Scabies and Atopic Dermatitis
Atopic Dermatitis (AD), Scabies
RecruitingPhase 4
Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia
Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia
Not yet recruitingObservational study
Gene Expression Analysis of Biofilm Formation and Antimicrobial Resistance in Clinical Methicillin-Resistant Staphylococcus Aureus
Staphylococcal Aureus Infection, Surgical Site Infection (SSI)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Daniel Betina principal investigator
Methodist Health System
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of MRSA, run by Methodist Health System at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Duration of therapy (time frame: 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Aug 2026.